Schaeffer Center expert Mireille Jacobson co-authored an op-ed in STAT examining why hospitals and health systems are not investing in palliative care despite research showing this type of therapy substantially improves outcomes for patients with serious illness.
Other featured articles
Pilot Funding Available for Researchers of Alzheimer’s, Aging
Pilot funding amounts range from $25,000 to up to $45,000. An informational session on the application process will be held over zoom on Thursday, December 9, 2021, at 10:00 a.m. pacific.
Applying for the 2022-2023 Roybal Center for Behavioral Interventions in Aging Pilot Projects
The Roybal Center for Behavioral Interventions in Aging seeks proposals for pilot projects that involve randomized controlled trials (RCTs).
The Costs of Developing Treatments for Alzheimer’s Disease: A Retrospective Exploration
With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development (R&D) investment in Alzheimer’s disease (AD), only five novel drugs—all for symptomatic treatment only—have reached FDA approval. Here, we estimate the costs of AD drug development during this period in the private sector.
NAM Expert Briefing on Behavioral and Social Science Research Questions Raised By the Use of Biomarkers for Alzheimer’s Disease Diagnostics
On June 28 and 29, 2021, the National Academies of Sciences, Engineering, and Medicine convened an expert meeting that addressed behavioral and social science research questions raised by the use of biomarkers and other measures for pre-clinical AD/ADRD diagnosis
About this section
People are living longer, which brings obvious benefits as well as considerable challenges — from Alzheimer’s and other age-related diseases to increased injuries, disabilities and poverty risks. Policymakers around the world rely on Schaeffer Center research and modeling tools for finding ways to help keep people as healthy as possible throughout their lives.